Anti-Ro52 Associated Interstitial Lung Disease: A Retrospective Analysis
Recommended Citation
Konja J, Major J, Thavarajah K, Abu Sayf A, Calo SM, Martirosov AL, Abdul Hameed AM. Anti-Ro52 Associated Interstitial Lung Disease: A Retrospective Analysis. Am J Respir Crit Care Med 2025; 211:A3539.
Document Type
Conference Proceeding
Publication Date
5-20-2025
Publication Title
Am J Respir Crit Care Med
Abstract
Rationale: Interstitial Lung Disease (ILD) is a common manifestation of myositis and is associated with worse morbidity and higher mortality. Antibodies to SSA antigen (Ro52/Ro60) consist of two distinct auto-antibody systems with different clinical associations. Ro52 antigen has been identified as a 52 kDa protein, belonging to the tripartite motif (TRIM) protein family and it is the most common myositis-associated autoantibody (MAA) found in patients with myositis. The co-existence of anti-Ro52 antibody with other myositis-specific autoantibodies (MSA) is thought to be predictive of an aggressive ILD course. This study aims to describe the characteristics of patients with ILD and a positive anti-Ro52 antibody. Methods: A retrospective cohort study of patients evaluated by a provider of the Henry Ford Health (HFH) ILD program and a positive anti-Ro52 antibody was performed. We collected demographic data including gender, age at diagnosis, ethnicity, insurance, and zip code as well as diagnostic makers such as serology results, pulmonary function tests (PFT), and imaging. We further reviewed evaluations by sub-specialties including rheumatology, dermatology, and neurology to assess confirmation of diagnosis of myositis. Descriptive statistics were performed. Categorical variables are reported as (n) total counts with percentages and continuous variables are reported with mean and standard deviation (SD). Univariate differences were assessed between anti-Ro52 positive patients with and without an MSA using Pearson's chi-squared test and t-tests. Results: Our study included 78 patients with a positive anti-Ro52 antibody evaluated by the HFH ILD provider team. Of these, 43 (55.1%) were female and 21 (26.9%) also had a positive MSA including 3 Jo1, 3 PL7, 2 PL12, 1 OJ, 4 MDA5, 4 TIFF, 3 NXP, 2 MI2, and 1 SRP autoantibodies. Evaluations included 41 (52.6%) by rheumatology, 26 (33.3%) by dermatology, and 31 (39.7%) by neurology and 17 (21.8%) had a confirmed diagnosis of myositis. Pulmonary Function Tests (PFT) of these patients showed mean forced vital capacity (FVC) percent of 62.4% (S.D 21.1%) and mean diffuse capacity of carbon monoxide (DLCO) percent of 38.6% (S.D 16.3%). High resolution CT imaging showed 64 of the patients (82.1%) with ground glass opacities, 11 (14.1%) with consolidations, 38 (48.7%) with reticulations, 43 (55.1%) with bronchiectasis, 19 (24.4%) with honeycombing, and 2 (2.6%) with air trapping. Conclusions: Our patient population represented primarily female gender with the majority not having confirmed myositis. When comparing patients with positive anti-Ro52 antibody with and without MSA, there were no statistically significant characteristics found.
Volume
211
First Page
A3539
